Liraglutide for weight management: a critical review of the evidence

A. Mehta; S. P. Marso; I. J. Neeland

doi:10.1002/osp4.84

journal article Open Access Dec 19, 2016

Liraglutide for weight management: a critical review of the evidence

A. Mehta

S. P. Marso I. J. Neeland

Obesity Science & Practice Vol. 3 No. 1 pp. 3-14 · Wiley

View at Publisher Save 10.1002/osp4.84

Abstract

SummaryObjectiveTo review the efficacy, safety, and clinical applicability of liraglutide for weight management from phase III clinical trials.MethodsA search of the English language literature was performed using PubMed search terms: “liraglutide”, “glucagon‐like peptide‐1 receptor agonist”, and “randomized clinical trial”. Articles and bibliographies relevant to the subject were reviewed and additional references known to the authors were included.ResultsFive randomized, placebo‐controlled trials of liraglutide for weight management were identified. In addition to recommended diet and physical activity, liraglutide consistently resulted in a 4 to 6 kg weight loss, with a greater proportion of patients achieving at least 5 and 10% weight loss compared with placebo. The most common adverse effects were gastrointestinal and primarily occurred early in the treatment course. Comparative data suggest that weight loss with liraglutide is greater than that seen with orlistat or lorcaserin, but slightly less that seen with phentermine/topiramate. Liraglutide 1.8 mg was recently shown to have cardiovascular benefit in a large outcomes trial; applicability of these results for the 3.0 mg formulation in a more diverse weight loss population at high cardiovascular risk is not currently known. Barriers to real‐world clinical use as a first‐line agent include gastrointestinal side effects, high cost, and need for injection.ConclusionsLiraglutide helps to induce and sustain weight loss in patients with obesity. Its efficacy is comparable to other available agents but it offers the unique benefit of improved glycemic control. Additional studies are needed to determine its long term efficacy and safety profile.

Topics

No keywords indexed for this article. Browse by subject →

References

29

[1]

(2015)

[2]

10.1155/2012/672658

[3]

10.1016/s0140-6736(09)61375-1

[4]

10.1038/ijo.2011.158

[5]

10.1038/ijo.2013.120

[6]

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management

Xavier Pi-Sunyer, Arne Astrup, Ken Fujioka et al.

New England Journal of Medicine 10.1056/nejmoa1411892

[7]

10.1001/jama.2015.9676

[8]

10.1038/ijo.2016.52

[9]

(2015)

[10]

10.1016/0014-5793(87)81430-8

[11]

10.1016/s0140-6736(87)91194-9

[12]

10.1007/bf01316798

[13]

10.1093/ajcn/68.3.525

[14]

10.1038/sj.ijo.0800818

[15]

10.1093/cvr/cvq271

[16]

10.1111/j.1463-1326.2012.01557.x

[17]

10.1210/endo.136.8.7628397

[18]

10.1007/s00125-005-1705-7

[19]

10.1016/j.clinthera.2009.11.034

[20]

An overview of the pharmacokinetics, efficacy and safety of liraglutide

Bruce Bode

Diabetes Research and Clinical Practice 10.1016/j.diabres.2011.12.015

[21]

Carel le RouxAA FujiokaK GreenwayF et al.Reduction in the risk of developing type 2 diabetes with liraglutide 3.0 mg in people with prediabetes from the SCALE Obesity and Prediabetes randomized double‐blind placebo‐controlled trial 2015. URLhttp://2015.obesityweek.com/app/uploads/2015/11/1105‐Thursday‐ObesityWeek‐2015‐Late‐Breaking‐TOS‐Poster‐Abstracts.pdf. (accessed June 2016.

[22]

Diagnosis and Classification of Diabetes Mellitus

Diabetes Care 10.2337/dc10-s062

[23]

10.2337/dc14-2883

[24]

10.1136/bmjopen-2012-001986

[25]

Guidance for Industry: Diabetes mellitus — evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes.2008. URLhttp://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf(accessed July 2016).

[26]

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

Steven P. Marso, Gilbert H. Daniels, Kirstine Brown-Frandsen et al.

New England Journal of Medicine 10.1056/nejmoa1603827

[27]

10.1001/jama.2016.7602

[28]

2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults

Michael D. Jensen, Donna H. Ryan, Caroline M. Apovian et al.

Journal of the American College of Cardiology 10.1016/j.jacc.2013.11.004

[29]

10.1210/jc.2014-3415

Cited By

252

Mitigating loss of lean muscle in GLP-1 and dual GLP-1/GIP agonists: Pipeline opportunities and limitations

Justin Hierholzer, Harrison Benson · 2026

Biochimica et Biophysica Acta (BBA)...

Revised definition of obesity in Asian Indians living in India

Anoop Misra, Naval K. Vikram · 2025

Diabetes & Metabolic Syndrome:...

Hormonal Gut–Brain Signaling for the Treatment of Obesity

Eun Roh, Kyung Mook Choi · 2023

International Journal of Molecular...

Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent

Syed Faizan Mehdi, Suma Pusapati · 2023

Frontiers in Immunology

A Systematic Review of the European Rapid Alert System for Food and Feed: Tendencies in Illegal Food Supplements for Weight Loss

Dorottya Koncz, Barbara Tóth · 2021

Frontiers in Pharmacology

Contemporary Classification of Glucagon-Like Peptide 1 Receptor Agonists (GLP1RAs)

Sanjay Kalra, Saptarshi Bhattacharya · 2021

Diabetes Therapy

GABA neurons in the nucleus tractus solitarius express GLP-1 receptors and mediate anorectic effects of liraglutide in rats

Samantha M. Fortin, Rachele K. Lipsky · 2020

Science Translational Medicine

Metrics

252

Citations

29

References

Details

Published: Dec 19, 2016
Vol/Issue: 3(1)
Pages: 3-14
License: View

Authors

A

A. Mehta

Department of Internal Medicine University of Texas Southwestern Medical Center Dallas TX USA

S

S. P. Marso

Research Medical Center Kansas City MO USA

I

I. J. Neeland

Division of Cardiology University of Texas Southwestern Medical Center Dallas TX USA

Cite This Article

A. Mehta, S. P. Marso, I. J. Neeland (2016). Liraglutide for weight management: a critical review of the evidence. Obesity Science & Practice, 3(1), 3-14. https://doi.org/10.1002/osp4.84

Liraglutide for weight management: a critical review of the evidence

You May Also Like